SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Clinuvel Pharmaceuticals (CLVLY)

CLVLY RSS Feed
Add CLVLY Price Alert      Hide Sticky   Hide Intro
Moderator: FarmaZutical
Search This Board: 
Last Post: 12/8/2017 5:03:06 PM - Followers: 14 - Board type: Free - Posts Today: 0

Clinuvel Logo           http://www.clinuvel.com/

General Information:
Clinuvel Pharmaceuticals is the leading photoprotective pharmaceutical company. Headquartered in Melbourne, Australia with offices in Baar, Switzerland, Singapore and Los Angeles Clinuvel trades as an ADR in the US.

Our Work: Source: http://www.clinuvel.com/en/our-work
Clinuvel is developing new drugs to improve the lives of individuals with severe skin disorders. Our lead technologies, SCENESSE® (afamelanotide 16mg) and CUV9900, are from a new class of drugs, known as melanocortins, which are based on the naturally occurring hormone α-MSH.

Mission Statement: Source: http://www.clinuvel.com/en/mission-statement
Clinuvel’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. Clinuvel develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.

Head Office: Source: 
http://www.clinuvel.com/en/contact
Clinuvel Pharmaceuticals Limited,
Level 14,
190 Queen Street,
Melbourne
VIC 3000
Australia
Tel: +61 3 9660 4900
Fax: +61 3 9660 4999

COMPANY HISTORY: (Source: http://www.clinuvel.com/en/company-history)


The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) and developing a proprietary, controlled-release implant formulation.

Since late 2005, Clinuvel has focused on developing SCENESSE® as a dermatological drug for individuals at greatest risk from visible and ultraviolet (UV) light and as a repigmentation therapy. The company has a particular focus on diseases where no existing preventative treatment exists.

Clinuvel commenced a clinical program in 2006 which focused on the rare disease erythropoietic protoporphyria (EPP), a metabolic disorder which causes painful burning reactions under the skin after even brief exposure to sunlight. The goal of Clinuvel’s EPP program is to prove that SCENESSE® can provide patients with EPP protection from sunlight by reducing the incidence and severity of EPP reactions. The ultimate objective is to provide a better quality of life for patients. Since the start of the EPP program, the company has involved more than 250 individuals with EPP in its global clinical trials. Between 2005 and today, clinical programs have also been conducted for individuals diagnosed with a range of disorders, including polymorphous light eruption, solar urticaria and organ transplant recipients who are susceptible to an extremely high rate of skin cancers.

In late 2009, Clinuvel announced that it had expanded its pipeline to include a second drug candidate, named CUV9900. Based on the same technology as SCENESSE®, CUV9900 is still in early stage development.

2010 was a pivotal year for Clinuvel. In May 2010, SCENESSE® became the first dermatological drug listed under the Italian 648/96 law, prior to its formal approval anywhere in the world. This listing allows Italian physicians to prescribe SCENESSE® to individuals with EPP with the cost of the drug reimbursed by the Italian National Health System (Sistema Sanitario Nazionale, SSN).

Later in 2010, Clinuvel also announced that it would expand its program for SCENESSE® to investigate the drug’s ability to repigment skin in the common pigmentation disorder vitiligo. Following regulatory and ethical approvals, Clinuvel’s International SCENESSE® Pilot Repigmentation Evaluation (INSPIRE) program commenced patient recruitment in 2011. A Phase II study was completed in the USA in 2013, showing that the drug had a good safety profile in vitiligo and may assist in faster repigmentation in patients when used in combination with narrowband UVB phototherapy. A Phase IIb study of the drug in vitiligo commenced in 2014 in Singapore.

In February 2012 Clinuvel lodged its first marketing authorisation application for SCENESSE® for EPP with the European Medicines Agency. In December 2014 the European Commission approved SCENESSE® for the prevention of phototoxicity in adult EPP patients.

As of December 2014, more than 900 individuals have been administered afamelanotide in Clinuvel’s clinical trials program and through compassionate use and special access schemes. To date, the drug has maintained a good safety profile in clinical trials.

 

SCENESSE® attains historic breakthrough European Marketing Authorisation

Clinuvel's Logo

European Medicines Agency CHMP approves novel drug for erythropoietic protoporphyria patients under exceptional circumstances (ART 14 (8) OF REGULATION (EC) NO 726/2004)

EXECUTIVE SUMMARY

  • SCENESSE® attains an historic breakthrough EMA approval for adult EPP patients extremely intolerant of light and UV
    Marketing authorisation in 31 European States
    Australian listed Clinuvel (ASX: CUV) has taken SCENESSE® from discovery to commercialisation
    SCENESSE® as the first drug for which patients’ and physicians’ clinical experiences were integrated EMA’s formal decision process
    Investor telephone conference-call Wednesday 29 October: 1800 Melbourne = 0900 Zurich = 0300 New York = 1500 Singapore. Details will be released to the ASX on Tuesday October 28.

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is proud to announce that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has voted in favour of marketing authorisation (MA) of Clinuvel’s drug SCENESSE® (afamelanotide 16mg) for adult patients with erythropoietic protoporphyria (EPP).

SCENESSE® is a first-in-class drug (belonging to a new drug category). EPP is a debilitating, rare genetic disorder clinically regarded as extreme intolerance to light and UV (phototoxicity). An estimated 10,000 EPP patients are affected worldwide, 45% of whom live within Europe.

Clinuvel conducted five trials testing SCENESSE® in approximately 350 adult EPP patients across Australia, Europe and the USA. The first EPP patient received the drug in 2006. Clinuvel submitted its dossier for EMA evaluation on 6 February 2012.

In September 2014, it was announced that the EMA - for the first time in its history - was incorporating patients’ and physicians’ clinical experiences with SCENESSE® in the CHMP’s decision process.

EMA Decision

On 23 October 2014 in its plenary session the CHMP voted in favour of marketing authorisation of SCENESSE®. This decision takes into account the challenges and limitations of conducting clinical trials in rare and severe disorders and allows access to treatment for patients without alternative medcine.1 Marketing authorisation is given for distribution of SCENESSE® across 31 European states.2 The CHMP’s decision will now be sent to the European Commission for formal ratification, expected within 67 days.

Clinuvel and the EMA have agreed to a comprehensive post-authorisation pharmacovigilance plan to monitor patients’ safety long term. SCENESSE® will be distributed through academic and specialised centres.

Comment

“On behalf of the Board, I congratulate shareholders and patients, experts in the field and Clinuvel’s teams around the world,” Clinuvel’s Chair, Stan McLiesh said. “I have witnessed from our staff a decade long dedication and an enormous zeal which has come together for patients and all stakeholders in a marvellous outcome, one rarely accomplished in pharmaceutical development and which is now unique to Australia.”

“Medical innovation requires an exceptional focus with a consistent strategy, passionate team and long term trust from patients, expert physicians and regulatory authorities worldwide,” Clinuvel’s CEO, Dr Philippe Wolgen said.

“Today I am excited but mostly proud that Clinuvel overcame a number of hurdles from having identified an unmet clinical need and taken a molecule from discovery to final commercial product. I congratulate our Acting Chief Scientific Officer Dr Wright and his entire team for the extraordinary achievement.”

“This outcome greatly impacts Clinuvel, our further operations and intrinsic value. The immediate goal is to distribute the drug to European patients in the coming months, while we owe it to our American and Asia-Pacific patient community to accelerate the regulatory process for them to gain access to SCENESSE®,” Dr Wolgen said.

FDA APPROVAL PROCESS


The FDA has recognised that afamelanotide meets an unmet clinical need and treats a severe genetic condition for patients who are life-long deprived of light. SCENESSE® was granted orphan drug designation by the FDA in 2008 for the treatment of EPP patients and Fast Track Designation (FTD) in 2016, allowing for a ‘rolling review’ of the NDA. The orphan drug designation provides R&D and review incentives for drugs which may not otherwise be commercially viable to develop, while FTD assists to ensure that innovative drugs reach the patient population earlier than would be the case during a standard review process. The ‘rolling review’ under the FTD allows the FDA to start the review of the scientific dossier only when all modules have been submitted and have passed formal validation, a two-month process after submission of the final NDA module.

CLINUVEL obtained a positive FDA answer on acceptance of the current safety data, as the FDA issued a carcinogenicity waiver in 2017.

This year CLINUVEL applied for a Priority Review which would secure a maximum review period of six months, compared to the standard ten months. It is expected that the FDA will answer the request for Priority Review at the start of the review period.

The FDA has initiated a regulatory pilot scheme to involve patients in explaining the impact of diseases on their lives. The Division for Dental and Dermatology Products hosted a scientific workshop on EPP in October 2016.

The NDA dossier is expected to be lodged in Q4 2017 or Q1 2018 which could lead to approval of Scenesse Q3 2018.
 

PIPELINE

Following the approval of Clinuvel’s lead product SCENESSE® (afamelanotide 16mg), the Company is actively pursuing an expanded pipeline of products from the melanocortin family, a class of drugs that includes afamelanotide. Two novel molecules have been announced: CUV9900 and VLRX001.

CUV9900

CUV9900 is an alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue. Initial research has shown that CUV9900 is a potent skin protectant. Clinuvel intends to launch CUV9900 in various new formulations. Formulation work has commenced and Clinuvel expects the first formulations to be available for clinical testing after the commercialisation of SCENESSE® in Europe.

VLRX001

VLRX001 is an addition to the family of melanocortin analogues which provoke increased and prolonged cellular activity. It contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH).

The VLRX001 development work was undertaken through Clinuvel’s majority owned Singaporean subsidiary, VALLAURIX and has leveraged the knowledge gained from long term experience with the clinical use of SCENESSE®.

Formulation work will focus on the development of VLRX001 for topical self-administration by patients. The transdermal product will initially be evaluated as adjuvant maintenance therapy in the depigmentation disorder vitiligo.

Overall, the development of VLRX001 is part of Clinuvel’s life cycle management of its portfolio of products to ensure long term use and value of its technology and assets. Clinuvel will hold all rights to the final product and indications through VALLAURIX.
 

UPDATED: NOV. 2017




 
SureTrader
Interactive Brokers Advertisement
CLVLY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#582   ghmm 12/08/17 05:03:06 PM
#581   What's going on here. Total lack of interest. sante1 12/08/17 12:06:23 PM
#580   CUV.AX is the Australian listing. Because it’s difficult FarmaZutical 12/04/17 06:48:45 AM
#579   CUV ASX closingprice today AUS $ 7,60 (nearly sante1 12/04/17 12:44:27 AM
#577   you need to take always the price-action of contrarian bull 12/01/17 10:55:00 AM
#576   From a technical point of vue CLVLY is sante1 12/01/17 10:44:57 AM
#575   Will the US $6,00 hold today. Absolutely no contrarian bull 12/01/17 09:13:43 AM
#574   Sorry AUS $8,01!. sante1 12/01/17 06:45:55 AM
#573   New low for CUV AUS $6,01! sante1 12/01/17 06:04:33 AM
#572   A fact is that the outcome of the sante1 11/30/17 10:50:49 AM
#571   I can't say that I'm very happy after FarmaZutical 11/30/17 08:53:43 AM
#570   Not only the SP tummbeled.The sentiment on the sante1 11/30/17 03:49:34 AM
#569   CLVLY closingprice yesterday, at the end of the sante1 11/30/17 12:56:50 AM
#568   OK I've had it with management/board ghmm 11/27/17 07:30:10 PM
#567   Don't know what they'll discuss/answer questions to but ghmm 11/27/17 06:57:53 PM
#566   Clinuvel AGM begins tonight 6 PM EST down FarmaZutical 11/27/17 11:43:52 AM
#565   Updated. Feel free to suggest changes and additions. FarmaZutical 11/26/17 02:12:39 PM
#564   Yes I am. Will work on it soon. FarmaZutical 11/24/17 08:03:54 AM
#563   Hi Farma, are you the Admin of the CUV88 11/24/17 07:38:58 AM
#562   Clinuvel high cash return sante1 11/21/17 01:29:07 PM
#561   i wonder if the CLVLY shareholder is well sante1 11/21/17 01:04:31 PM
#560   Laughable performance, CLVLY down. CUV in the uptrend. sante1 11/21/17 12:29:51 PM
#559   Closingprice UR9 Frankfurt €5,90 (US $6,9242) sante1 11/20/17 03:01:21 PM
#558   Clinuvel UR9 Frankfurter borse €5,915 sante1 11/20/17 11:11:16 AM
#557   closingprice today $6,80, volume 500! sante1 11/20/17 10:41:03 AM
#556   What's going on here? Clinuvel a company with sante1 11/16/17 04:33:31 PM
#555   Market getting exhausted here on the Nasdaq? Looking sante1 11/15/17 11:42:13 AM
#554   I’m not too worried about a CRL. With FarmaZutical 11/15/17 03:42:30 AM
#553   Todays Closingprice CUV $8,79 (US $6,66) sante1 11/15/17 01:00:38 AM
#552   For the one who orchestrates the SP of sante1 11/15/17 12:40:06 AM
#551   No I haven't either. ghmm 11/14/17 10:37:00 AM
#550   Ghmm, have you ever heard about priority review FarmaZutical 11/14/17 10:11:07 AM
#546   Great article! -J Jestiron 11/12/17 10:19:37 AM
#545   US $21-$28 fair value sante1 11/11/17 01:41:11 AM
#544   Seeking Alpha Article https://seekingalpha.com/article/4123549-clinuvel-high-cas ghmm 11/10/17 05:28:33 PM
#543   Price results CUV today sante1 11/08/17 12:37:33 AM
#542   Price query CUV 7/11 sante1 11/08/17 12:23:44 AM
#541   Price query CUV 7/11 sante1 11/08/17 12:23:37 AM
#540   Good post. FarmaZutical 11/07/17 12:02:30 PM
#539   Thanks for the reply... I'm usually on contrarian bull 11/07/17 09:18:29 AM
#538   PW = CEO Philippe Wolgen ghmm 11/07/17 09:11:09 AM
#537   absolute have no idea who PW realy is contrarian bull 11/07/17 08:58:05 AM
#536   On Uniform pricing ghmm 11/07/17 04:37:52 AM
#535   That's too late, much too late. Furthermore Holland sante1 11/07/17 01:42:08 AM
#534   I agree on all counts. The uniform pricing FarmaZutical 11/07/17 12:15:15 AM
#533   Stop uniform pricing!!!! sante1 11/06/17 11:55:29 PM
#532   Considering the shares outstanding the volume while much ghmm 11/06/17 04:37:54 PM
#531   Homm might be spot on in his valuation FarmaZutical 11/06/17 04:29:59 PM
#530   Florian seems to be reasonable in his previous Jestiron 11/06/17 04:09:41 PM
#529   I’m a bit worried that Florian Homm is FarmaZutical 11/06/17 03:29:57 PM
PostSubject